NasdaqGM - Delayed Quote USD

Graniteshares 2x Short TSLA Daily ETF (TSDD)

9.15 +1.36 (+17.46%)
At close: October 11 at 4:00 PM EDT
8.96 -0.19 (-2.08%)
Pre-Market: 9:29 AM EDT
Loading Chart for TSDD
DELL
  • Previous Close 7.79
  • Open 9.01
  • Bid 9.14 x 4500
  • Ask 9.17 x 2600
  • Day's Range 8.79 - 9.36
  • 52 Week Range 6.41 - 38.44
  • Volume 2,586,497
  • Avg. Volume 1,646,575
  • Net Assets 17.28M
  • NAV 9.15
  • PE Ratio (TTM) --
  • Yield 2.68%
  • YTD Daily Total Return -41.23%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 1.50%

The fund is an actively managed exchange traded fund that attempts to replicate the 2 times inverse (-200%) daily percentage change of the underlying stock by entering into a swap agreement on the underlying stock. The fund advisor aims to generate the inverse daily performance of the underlying stock for a single day.

Graniteshares

Fund Family

Trading--Inverse Equity

Fund Category

17.28M

Net Assets

2023-08-21

Inception Date

Performance Overview: TSDD

View More

Trailing returns as of 10/11/2024. Category is Trading--Inverse Equity.

YTD Return

TSDD
41.23%
Category
--
 

1-Year Return

TSDD
39.97%
Category
--
 

3-Year Return

TSDD
0.00%
Category
--
 

People Also Watch

Related ETF News

View More

Research Reports: TSDD

View More
  • Raising target price to $174.00

    ICU MEDICAL INC has an Investment Rating of HOLD; a target price of $174.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • Raising target price to $172.00

    ICU MEDICAL INC has an Investment Rating of HOLD; a target price of $172.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • LivaNova Earnings: Strong Execution and New Product Cycle Support Outperformance

    UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

    Rating
    Price Target
     
  • Medtronic Earnings: New Products Support a Strong Start to the New Fiscal Year

    One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

    Rating
    Price Target
     

Related Tickers